Join experts from Charles River & Quotient Sciences for a complimentary lunch seminar on Thursday, March 30th from 10:30am at the Radisson Blu Hotel, Basel, Switzerland.
Seminar title: 'Integrated Strategies for Accelerating from Discovery to IND and Beyond: Charles River & Quotient Sciences Collaboration'
Thursday, Mar. 30th
The early drug development roadmap from discovery to preclinical IND and onwards can be challenging and difficult to navigate. Understanding each critical step, its timings, and potential risks at each stage requires extensive expertise. Collaborating with experienced service providers can help streamline this process, integrating all the necessary activities, removing potential hurdles, and allowing a seamless transition from discovery into clinical development.
Charles River & Quotient Sciences have formed a collaboration to accelerate the path to the clinic to better support customers. They have developed an integrated offering that seamlessly bridges molecules from early discovery to clinical proof-of-concept (POC) and beyond. Charles River’s deep expertise in medicinal chemistry, biology, DMPK, early pharmaceutics and non-clinical safety, coupled with Quotient Sciences’ expert knowledge of drug substance synthesis, drug product development & manufacturing and clinical testing services offer a solution under a single program of work. This tight integration of expertise and activities streamlines the outsourcing model, providing earlier and more informed decision-making, efficient technology transfer, and joint problem-solving.
In this presentation, senior leaders from Charles River and Quotient Sciences discuss how this collaboration helps customers by bringing expert knowledge, removing obstacles from the critical path, reducing development risks, and shortening the pathway to clinical development. Through case studies, they will demonstrate how an integrated program provides customers with the full set of deliverables required to be “clinic ready”, and how this seamless transition between providers can improve the chances of clinical success.
Key topics covered include:
- The benefits of an integrated approach to accelerate to IND and beyond
- How this collaboration seamlessly delivers these integrated programs of work
- How technical transfers are achieved between organizations and how this can benefit clients in both time and cost saving
- A timeline overview for each stage of the development process
- Case studies that demonstrate the benefits of an integrated discovery-to-clinic approach
Combined, these service providers have over >100 years of experience in the drug development space and have worked with 1000s of molecules across all stages of development, cementing them as trusted industry experts.
- Eleanor Row, Executive Director of Commercial
About Charles River
Every complex discovery program faces a unique set of challenges. Whether it's a resource gap, lack of infrastructure, or an unexpected scientific result, navigating around potential pitfalls is essential for advancing your program successfully. Charles River has successfully identified and assessed novel therapies, with over 420 patents and 92 preclinical drug development candidates delivered to our clients since 2001. Our chemistry, biology, ADME, toxicology, and pharmaceutical sciences teams work closely together to identify and optimize the best compound candidates from the earliest stages of hit identification all the way through to FIH and beyond.
About Quotient Sciences:
Quotient Sciences is a drug development and manufacturing accelerator supporting customers across the entire development pathway from candidate selection to commercial launch. We deliver uniquely integrated programs and a range of tailored services that dramatically shorten drug development times. We’re driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.